International Research Journal of Medicine and Surgery (IRJMedS), 2025; 2(2): 8-12 IRJMedS

Review Article | ISSN (O): 3048-6955 DOI: 10.47857/irjmeds.2025.v02i02.025

The Role of Cytochrome P450 in the Metabolism of Commonly Used Dental Drugs

Saubhagya S Agrawal[1]*, Mohammad Zanul Abedeen[2]

[1]Department of Oral and Maxillofacial Surgery, Teerthanker Mahaveer Dental College & Research Centre, Moradabad, Uttar Pradesh, India, [2]Department of Oral Pathology and Microbiology, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, Uttar Pradesh, India. *Corresponding Author's Email: saubhagyaagarwal2@gmail.com

Abstract

Response to drug therapy varies considerably from individual to individual, and their clinical outcomes, ranging from treatment failure to adverse drug reactions, can be largely attributed to drug metabolism. Cytochrome p450 enzymes play a crucial role in the metabolism of a wide variety of medications, including medications used in dentistry. Cytochrome P450 enzymes show variability due to genetic polymorphisms, drug-drug interactions, and certain patient factors, which can significantly impact the efficacy of drugs and their safety range. It is essential to understand the metabolic pathways of these enzymes to optimize drug selection, dosage, and minimize the adverse effects or therapeutic failures of the medications prescribed to patients. This review explores the various isoforms of CYP enzymes, particularly CYP3A4, CYP2C9, and CYP1A2, and their impact on the metabolism of frequently prescribed medications, such as analgesics, antibiotics, anti-inflammatory agents, and anesthetics in dentistry. The following article highlights the clinical implications, the knowledge of CYP450-mediated metabolism in dentistry, and areas of future research.

Keywords: Analgesics, Cytochrome P450, Drugs, Interactions, Metabolism, Over the Counter.

Introduction

Analgesics and antibiotics are the most frequently prescribed medications for pain, infection, inflammation and post-operative discomfort by the dentists. Analgesics are classified as opioid analgesics or non-opioid analgesics also known as non-steroidal anti-inflammatory drugs (NSAIDs). A large number of drugs are metabolized by cytochrome p450 enzymes present in the endoplasmic reticulum cells of the liver. Cytochrome (CYP) enzymes belong to a superfamily of heme-containing monooxygenases which are responsible for the breakdown and expression of numerous medications affecting their efficacy and duration of action (1). A different gene encodes every enzyme which belongs to this superfamily. CYP enzymes undergo a variety of other reactions, each with slight variations depending on the enzyme and substrate involved. However their primary action is to add oxygen atoms to the substrate. Drugs are metabolized, detoxified and eliminated by the help of CYP enzymes. The activity of CYP enzymes is influenced by numerous factors including age, disease status, genetic polymorphisms, exposure to other medicines, and environmental factors. These factors may result in significant differences in drug metabolism, which could have a substantial impact on the safety and effectiveness of medications (2).

Cytochrome P450 (CYP) enzymes catalyze several important chemical reactions that facilitate the breakdown of drugs in the body. These reactions primarily involve adding an oxygen atom to the drug molecule, which enables its removal from the body. Common types of responses performed by CYP enzymes include hydroxylation (the addition of a hydroxyl group), demethylation (the removal of a methyl group), epoxidation (the formation of an epoxide group), and dealkylation (the removal of an alkyl group). These reactions happen through a process where the CYP enzyme uses oxygen and electrons to modify the drug. Understanding these specific reactions is important because they affect how quickly drugs are metabolized and whether harmful by-products are formed (3).

As CYP450 enzymes are involved in the biotransformation of dental medications, all the patients receiving drug therapy should be evaluated for any concurrent medications that may

(Received 14th January 2025; Accepted 24th April 2025; Published 30th May 2025)

interact with the activity of another drug based on their effects on CYP activity. The importance of customised treatment for every individual based on their systemic health and underlying medical conditions is highlighted by the cytochrome enzymes (4). CYP enzyme causes induction of drugs which can result in increasing the metabolism and elimination of drugs hence diminishing their therapeutic effects. CYP inhibition can either result in drug accumulation or reduced drug metabolism leading to possible clinical toxicity (5). The impact of CYP inducers and inhibitors on drug metabolism can vary greatly depending on factors such as the specific inducer or inhibitor involved, its dosage, duration of administration, and individual patient characteristics like age, genetics, and liver function. For example, strong CYP3A4 inhibitors like ketoconazole can significantly increase plasma levels of drugs metabolized by this enzyme even at low doses, raising toxicity risk. In contrast, mild inhibitors may have minimal clinical impact (6). Therefore, understanding these contextual factors is essential for accurately predicting drug interactions and optimizing individualized treatment regimens. Healthcare practitioners and dentists should obtain a complete medical history of patients including prescribed medicines, over the counter drugs and herbal supplements to avoid possible drug-drug interactions mediated by CYP enzymes. It is important to choose appropriate treatment and dosage of drugs by understanding patients' metabolism, considering the age, liver function and other medications history in order to avoid and minimise adverse effects (7). The cytochrome p450 connection is showed in Figure 1 below.



Figure 1: The Cytochrome P450 Connection

An array of endogenous and exogenous factors influence the activity and production of CYP450 enzymes. As age advances, blood flow to the liver becomes sluggish, resulting in reduced enzymatic activity and affecting drug metabolism. On the other hand, newborns have immature liver enzyme systems resulting in decreased clearance of drugs causing their accumulation. The

expression of cytochrome enzymes is greatly influenced by gender, hormonal changes, diet, alcohol, environmental factors and lifestyle (8). Smoking produces CYP1A2, which boosts the metabolism of particular medications including caffeine and theophylline. Hepatic illness reduces the functional ability of hepatic enzymes, therefore altering drug metabolism and raising the risk of toxicity. Moreover, drug-drug interactions are crucial; certain drugs work as inducers, while others as enzyme inhibitors, thereby significantly affecting the pharmacokinetics and therapeutic efficacy of drugs taken concurrently (9).

In addition to CYP-mediated metabolism, other enzymatic pathways, such as plasma and tissue esterases, play a crucial role in the metabolism of certain dental drugs. For example, articaine is primarily metabolized by plasma esterases rather than CYP enzymes, which contributes to its relatively safer profile in patients with impaired liver function. Comparing these non-CYP pathways alongside CYP metabolism is crucial for a comprehensive understanding of drug clearance mechanisms in dental pharmacology and for tailoring treatment choices based on patient-specific factors (10).

Discussion

Dental practitioners often prescribe various pharmacological agents, many of which are metabolized via specific cytochrome p450 pathways. Analgesics, including paracetamol (acetaminophen), are predominantly metabolized by the enzymes CYP1A2 and CYP2E1. Individuals with CYP2E1 polymorphisms or hepatic impairment exhibit an elevated risk of hepatotoxicity resulting from the accumulation of toxic metabolites (11). Nonsteroidal Anti-inflammatory drugs, such as ibuprofen and diclofenac, are primarily metabolized by CYP2C9. Genetic variations in this enzyme can influence drug efficacy and increase the risk of gastrointestinal and renal side effects (12). Antibiotics frequently utilized in dentistry are also subject to CYP metabolism. Metronidazole is metabolized by CYP3A4 and CYP2A6, whereas clindamycin experiences hepatic metabolism with limited involvement of cytochrome p450 enzymes. Macrolides Including erythromycin and clarithromycin, are metabolized by CYP3A4 and serve as strong inhibitors of this enzyme, which may result in considerable drug interactions when used concurrently with other medications that are also metabolized by CYP3A4 (13). Local anesthetics such as lidocaine undergo metabolism via CYP1A2 and CYP3A4. Patients with impaired liver function may exhibit delayed clearance and an elevated risk of toxicity. Sedatives and anxiolytics, such as diazepam and midazolam, are metabolized by CYP3A4 and CYP2C19 enzymes. Their sedative effects may be enhanced when used in conjunction with other central nervous system depressants or CYP inhibitors (14). Antifungals like fluconazole and ketoconazole are recognized as CYP inhibitors, particularly of CYP3A4, and can markedly elevated plasma levels of co-administered medications, requiring meticulous evaluation to prevent adverse outcomes. Comprehending these metabolic pathways is crucial for ensuring safe prescribing and reducing the likelihood of drug interactions and dental practice (15). Genetic polymorphisms in CYP enzymes, such as *CYP2C9*2**, *CYP2C9*3**, and *CYP2D6*4**, significantly affect how dental drugs like NSAIDs and opioids are metabolized, impacting both efficacy and risk of side effects. Despite their importance, these variations are often overlooked in dental practice due to limited genetic testing and research in diverse populations. Future work should focus on integrating pharmacogenetic profiling to personalize dental drug therapy, improving safety and treatment outcomes (16). All commonly used dental drugs and CYP450 interactions are enlisted in Table 1 below.

Table 1: Commonly Used Dental Drugs and CYP450 Interactions

Drug	CYP450 Isoenzymes Involved	Metabolic Role	Clinical Implications
Paracetamol	CYP2E1, CYP1A2	Formation of toxic metabolite (NAPQI)	Risk of hepatotoxicity in overdose
Ibuprofen	CYP2C9	Oxidative metabolism	Increased toxicity in poor metabolizers
Diclofenac	CYP2C9, CYP3A4	Hydroxylation and conjugation	Increased risk of liver injury in poor metabolizers

Lidocaine	CYP1A2, CYP3A4	Hepatic metabolism	Elevated levels in hepatic disease or CYP inhibition
Articaine	Minimal CYP involvement	Mainly plasma esterases	Safer in hepatic impairment
Amoxicillin	None	Not metabolized by CYP450	Low interaction potential; preferred in elderly patients
Metronidazole	CYP2C9 inhibitor	Potentiates warfarin activity	Monitor INR, bleeding risk
Erythromycin	CYP3A4	CYP3A4 inhibition	Risk of toxicity or accumulation when combined with CYP3A4 substrates
Alprazolam	CYP3A4	Hepatic metabolism	Interaction with CYP3A4 inhibitors may increase sedation/toxicity
Diazepam	CYP3A4, CYP2C19	Hepatic metabolism	Enhanced sedative effects with CYP inhibitors or CNS depressants
Celecoxib	CYP2C9	Oxidative metabolism	Risk of increased toxicity or reduced efficacy in poor metabolizers
Clonazepam	CYP3A4	Hepatic metabolism	Potential for enhanced sedation and toxicity with CYP3A4 inhibitors
Ketorolac	CYP2C9	Oxidative metabolism	Similar risks as other NSAIDs metabolized by CYP2C9

Dentists should have complete and accurate knowledge about the metabolism of cytochrome p450 enzymes to ensure safe prescription practices. Finding the specific CYP isoenzymes involved in the metabolism of commonly used dental drugs helps one to predict changes in therapeutic efficacy and reduce the risk of adverse drug reactions. Particularly for patients on systemic drugs for chronic conditions, doctors have to be careful of possible drug-drug interactions since many of these drugs either function as CYP inhibitors or inducers and use similar metabolic pathways (17). Prescribing macrolide antibiotics, sedatives, or NSAIDs with caution becomes especially important considering probable interactions with cardiovascular medications, anticoagulants, or CNS depressants. Estimating variations in drug metabolism calls for a thorough examination of the patient's medical record including current medications, liver performance, and lifestyle decisions including alcohol or smoking. Moreover, explaining to patients the need of revealing all medicines, including over-the-counter drugs and herbal supplements, can improve safety and treatment results. Using a tailored approach and maintaining understanding of CYP-related pharmacokinetics can help dental practitioners provide safer, more successful and patient-centered treatment (18).

Conclusion

As polypharmacy continues to expand, the probability of adverse drug interactions in dentistry also increases. Ensuring patients' medical histories are an essential factor to consider, as the CYP enzyme system affects the metabolic fate, duration, and adverse effects of dental medications. Understanding the inducing and inhibiting effects of cytochrome enzymes will help practitioners avoid potential side effects. Patients with underlying Liver dysfunction, genetic polymorphisms, or on multiple drug regimens require customized drug therapy due to the complex network of isoenzymes of cytochrome. Practitioners can make more informed decisions about drug choice, dosage, and drug interaction expectations, thereby improving patient safety and the efficacy of treatment. An advanced strategy of incorporating CYP450 profiling into the dental field may become a useful technique for providing individualized and exact dental treatment as pharmacogenetics develops.

Abbreviation

None.

Acknowledgment

None.

Author Contributions

All authors are equally contributed.

Conflict of Interest

The authors declare no conflict of interest.

Ethics Approval

Not applicable.

Funding

None.

References

1. Becker DE, Phero JC. Drug therapy in dental practice: nonopioid and opioid analgesics. Anesth Prog. 2005 Winter;52(4):140-9.
2. Gordeziani MS, Varazi TG, Pruidze MV. Structural–functional organization of cytochrome P450 containing monooxygenase and some aspects of modeling. Annals of Agrarian Science. 2016 Jun 1;14(2):82-94.
3. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci. 2021 Nov 26;22(23):12808.
4. Guengerich FP. Mechanisms of Cytochrome P450-Catalyzed Oxidations. ACS Catal. 2018 Dec 7;8(12):10964-10976.
5. Hersh EV, Moore PA. Adverse drug interactions in dentistry. Periodontology 2000. 2008 Feb 1;46(1).
6. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics. 2020 Sep 4;12(9):846.
7. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Current drug targets. 2018 Jan 1;19(1):38-54.
8. Hersh EV, Moore PA. Drug interactions in dentistry: the importance of knowing your CYPs. The Journal of the American Dental Association. 2004 Mar 1;135(3):298-311.
9. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and therapeutics. 2013 Apr 1;138(1):103-41.
10. Snoeck M. Articaine: a review of its use for local and regional anesthesia. Local Reg Anesth. 2012;5:23-33.
11. Hollenberg PF. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug metabolism reviews. 2002 Jan 1;34(1-2):17-35.
12. Gonzalez FJ. cyp2e1. Drug metabolism and disposition. 2007 Jan 1;35(1):1-8.
13. Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics and pain treatment with a focus on non-steroidal anti-inflammatory drugs (NSAIDs) and antidepressants: a systematic review. Pharmaceutics. 2022 Jun 1;14(6):1190.
14. Byrne BE. Drug interactions: a review and update. Endodontic topics. 2003 Sep;4(1):9-21.
15. Bosenberg AT. Local anesthetic agents. Smith's Anesthesia for Infants and Children E-Book. 2016 Oct 15:214.
16. Ouellet D, Bramson C, Roman D, Remmers AE, Randinitis E, Milton A, Gardner M. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. Br J Clin Pharmacol. 2007 Jan;63(1):59-66.
17. Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Current drug metabolism. 2014;15(7):651-679.
18. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. International journal of molecular sciences. 2021 Nov 26;22(23):12808.